CV Sciences ((CVSI)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CV Sciences struck a cautiously optimistic tone in its latest earnings call, highlighting steady margin gains, disciplined cost control, and a move to positive operating cash flow even as revenue and unit volumes declined. Management argued that diversification beyond cannabinoids, operational insourcing, and recent acquisitions are setting a credible path toward breakeven, though low cash levels and regulatory uncertainty remain significant overhangs.
Revenue Resilience Despite Headwinds
Revenue for Q1 2026 came in at $3.2 million, down 11% year over year but only 3% lower than Q4 2025, underscoring some resilience in a soft CBD market. Executives framed the modest sequential decline as evidence that the core business is stabilizing despite ongoing category contraction and regulatory noise.
Improved Gross Margin Year-over-Year
Gross margin expanded to 48.9% in Q1 2026 from 46.0% a year earlier, an improvement of 2.9 percentage points. Management credited lower product costs and progress on insourcing manufacturing, while acknowledging some pressure versus the prior quarter’s 50.5% level.
Meaningful Cost Reductions
Operating expenses fell about 13.3% to $1.9 million, reflecting tightened SG&A as the company cut legal and professional fees and trimmed marketing. Administrative efficiencies also contributed to the leaner cost base, helping offset weaker top-line performance.
Adjusted EBITDA and Cash Flow Improvement
Adjusted EBITDA loss narrowed to $0.1 million from a $0.3 million loss in Q1 2025, signaling improving underlying profitability. CV Sciences also delivered roughly $0.1 million of positive operating cash flow, a sharp swing from cash usage in the prior-year period.
Progress Toward Breakeven and Balance Sheet Moves
The company emphasized that it is closing in on cash flow breakeven, ending the quarter with about $0.3 million in cash, slightly above year-end levels. Management amended a note payable into a convertible structure to bolster flexibility, framing the move as part of a broader effort to shore up the balance sheet.
Product and Channel Momentum
CV Sciences highlighted the launch of PlusHLTH EMPOWR, a non-cannabinoid product featuring 20 grams of protein, 5 grams of creatine, and probiotics, as a key step in diversifying its portfolio. Direct-to-consumer sales remained robust, contributing 44% of revenue, and early feedback from consumers and retailers on the new offerings was described as encouraging.
Strategic M&A and Operational Insourcing
The company’s acquisitions of Cultured Foods and Elevated Softgels are beginning to contribute to scale and diversification, while boosting supply chain flexibility. Management expects strategic insourcing of manufacturing to further lower costs and shorten time-to-market, with synergies slated to build in the second half of 2026.
Market Position and Emerging Regulatory Tailwinds
Despite industry turbulence, CV Sciences said it has maintained the number-one hemp extract brand position in natural product retail, citing SPINS data. Management also pointed to emerging federal developments that could expand access and channels for hemp-derived products, characterizing them as early signs of potential regulatory tailwinds.
Inventory and Working Capital Discipline
Inventory declined to $3.9 million from $4.1 million at year-end, reflecting a tighter grip on working capital. The company noted improvements in collections and payables oversight as it works to align stock levels with softer category demand.
Top-Line Pressure and Unit Sales Decline
Revenue fell 11% year over year and unit volumes slid roughly 12%, underscoring persistent pressure in the CBD category. Management acknowledged that softer demand and a shrinking market are weighing on growth, making share gains and diversification critical to offsetting declines.
Sequential Gross Margin Compression
While year-over-year margins improved, gross margin slipped from 50.5% in Q4 2025 to 48.9% in Q1 2026. The company attributed the quarter-to-quarter compression to mix and operational factors, indicating that sustaining margin gains remains a work in progress.
Widening GAAP Net Loss
GAAP net loss widened to $0.6 million from $0.1 million a year ago, highlighting that headline profitability deteriorated even as adjusted metrics improved. Management noted that comparisons are complicated by prior-year items and stressed that underlying trends are moving in the right direction.
Operating Loss Despite Structural Cost Cuts
CV Sciences reported an operating loss of $0.3 million versus a small operating profit in the prior-year period, which had benefited from a one-time payroll tax accrual reversal. Excluding that tailwind, executives argued that structural cost cuts are beginning to show through, though not yet enough to fully offset revenue softness.
Low Cash Balance and Liquidity Risk
The company’s roughly $0.3 million cash balance remains modest, leaving limited room for error if trends worsen. Management conceded that there could be modest cash usage in the near term, reinforcing that careful liquidity management and access to capital are critical.
Regulatory Uncertainty and Product Risk
Executives flagged ongoing regulatory uncertainty, including recent federal actions that may necessitate product changes or limit certain offerings if not revised. They cautioned that shifting rules pose execution and revenue risks, even as the company seeks to position itself to benefit from more favorable frameworks over time.
Competitive and Contracting Market
The CBD landscape remains fragmented and intensely competitive, with the overall category contracting and putting pressure on all players. CV Sciences stressed that consolidation, operational discipline, and product innovation will be essential to defending and expanding its share.
Forward-Looking Guidance and Strategic Priorities
Looking ahead, management reiterated expectations of generating positive operating cash flow in the second half of 2026 as cost reductions, insourcing benefits, and acquisition synergies ramp. The company plans to roll out additional non-cannabinoid products, selectively expand internationally, and pursue emerging health-program channels, while acknowledging that broader adoption visibility may take until late 2026 and 2027.
CV Sciences’ latest call painted a picture of a company tightening its operations and pivoting its product mix even as it navigates a shrinking, heavily regulated CBD market. Investors will be watching whether margin gains, cash discipline, and diversification can offset top-line pressures and liquidity risk, and ultimately translate into sustainable profitability.